PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 434 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... December 19, 2024 EMA Recommends Extension of Indications for Lorlatinib December 20, 2021 ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) July 28, 2020 8-Year-Old Cancer Survivor Breaks National Record for Girl Scout Cookie Sales April 1, 2021 Load more HOT NEWS Approximately 1 Million of New Maternal Orphans Due to Cancer in... Atlantic rowing trio smash world record and raise thousands for cancer... 4 Tips from Oncology Dietitians for Healthier Eating During Cancer NHS lung cancer patients in England to get early access to...
